EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study

Chao-Hua Chiu, Meng-Chih Lin, Yu-Feng Wei, Gee-Chen Chang, Wu-Chou Su, Te-Chun Hsia, Jian Su, Anne Kuei-Fang Wang, Min-Hua Jen, Tarun Puri, Jin-Yuan Shih

Targeted Oncology · 2023

DOI: 10.1007/s11523-023-00975-5 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Targeted Oncology, 2023. Verfasst von Chao-Hua Chiu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Taipei Medical University Hospital and Taipei Veterans General Hospital, Taipei City, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Dermatitis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This study was funded by Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In RELAY, a randomized, double-blind, phase III trial investigating the efficacy and safety of ramucirumab+erlotinib (RAM+ERL) or ERL+placebo (PBO) in patients with untreated, stage IV, epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), RAM+ERL demonstrated superior progression-free survival (PFS) versus PBO+ERL, with no new safety signals. OBJECTIVE: The aim of this paper was to report efficacy and tolerability findings for the Taiwanese participants of RELAY. PATIENTS AND METHODS: Patients were randomized 1:1 to RAM+ERL or ERL+PBO. Primary endpoint was investigator-assessed PFS. Secondary endpoints included objective response rate (ORR), duration of response (DoR) and tolerability. Data for the current analysis are reported descriptively. RESULTS: In RELAY, 56 Taiwanese patients were enrolled; 26 received RAM+ERL, 30 received ERL+PBO. The demographic profile of the Taiwanese subgroup was consistent with that of the overall RELAY population. Median PFS for RAM+ERL/ERL+PBO, respectively, was 22.05 months/13.40 months (unstratified hazard ratio 0.4; 95% confidence interval 0.2-0.9); ORR was 92%/60%; median DoR was 18.2 months/12.7 months. All patients experienced one or more treatment-emergent adverse events (TEAEs); those most commonly reported were diarrhea and dermatitis acneiform (58% each) for RAM+ERL and diarrhea (70%) and paronychia (63%) for PBO+ERL. Grade ≥ 3 TEAEs were experienced by 62%/30% of RAM+ERL/PBO+ERL patients, respectively, and included dermatitis acneiform (19%/7%), hypertension (12%/7%), and pneumonia (12%/0%). CONCLUSIONS: PFS for the Taiwanese participants of RELAY receiving RAM+ERL versus ERL+PBO was consistent with that in the overall RELAY population. These results, together with no new safety signals and a manageable safety profile, may support first-line use of RAM+ERL in Taiwanese patients with untreated EGFR-mutant stage IV NSCLC. TRIAL REGISTRATION: www. CLINICALTRIALS: gov , NCT02411448.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsDermatitisHumansErlotinib HydrochlorideAntineoplastic Combined Chemotherapy ProtocolsErbB ReceptorsDiarrheaMutationRamucirumab

Substanzen

Erlotinib HydrochlorideErbB ReceptorsRamucirumab

Autor:innen und Institutionen

  • Taipei Medical University Hospital and Taipei Veterans General Hospital, Taipei City, Taiwan.
  • Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan.
  • E-Da Hospital, Kaohsiung City, Taiwan.
  • School of Medicine, and Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan.

Förderung

  • This study was funded by Eli Lilly and Company

Zitieren

APA

Chiu, C. H., Lin, M. C., Wei, Y. F., Chang, G. C., Su, W. C., Hsia, T. C., Su, J., Wang, A. K., Jen, M. H., Puri, T., & Shih, J. Y. (2023). Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study. Targeted Oncology. https://doi.org/10.1007/s11523-023-00975-5

Vancouver

Chiu CH, Lin MC, Wei YF, Chang GC, Su WC, Hsia TC, et al. Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study. Targeted Oncology. 2023. doi:10.1007/s11523-023-00975-5

BibTeX
@article{Chiu2023,
  author = {Chiu, Chao-Hua and Lin, Meng-Chih and Wei, Yu-Feng and Chang, Gee-Chen and Su, Wu-Chou and Hsia, Te-Chun and Su, Jian and Wang, Anne Kuei-Fang and Jen, Min-Hua and Puri, Tarun and Shih, Jin-Yuan},
  title = {Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study},
  journal = {Targeted Oncology},
  year = {2023},
  doi = {10.1007/s11523-023-00975-5}
}
Kostenlos starten →